Hasil Pencarian - Dan G. Duda

Perbaiki Hasil
  1. 1
    Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigms

    Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigms oleh Jiang Chen, Dan G. Duda

    Diterbitkan 2020-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Leveraging Blood-Based Diagnostics to Predict Tumor Biology and Extend the Application and Personalization of Radiotherapy in Liver Cancers

    Leveraging Blood-Based Diagnostics to Predict Tumor Biology and Extend the Application and Personalization of Radiotherapy in Liver Cancers oleh Franziska Hauth, Hannah J. Roberts, Theodore S. Hong, Dan G. Duda

    Diterbitkan 2022-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation.

    VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation. oleh Michelle R Dawson, Dan G Duda, Sung-Suk Chae, Dai Fukumura, Rakesh K Jain

    Diterbitkan 2009-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Blockade of VEGFR2 and not VEGFR1 can limit diet-induced fat tissue expansion: role of local versus bone marrow-derived endothelial cells.

    Blockade of VEGFR2 and not VEGFR1 can limit diet-induced fat tissue expansion: role of local versus bone marrow-derived endothelial cells. oleh Joshua Tam, Dan G Duda, Jean Y Perentes, Rehan S Quadri, Dai Fukumura, Rakesh K Jain

    Diterbitkan 2009-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway

    VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway oleh Zhangya Pu, Dan G. Duda, Yuanyuan Zhu, Siya Pei, Xiaofang Wang, Yan Huang, Panpan Yi, Zebing Huang, Fang Peng, Xingwang Hu, Xuegong Fan

    Diterbitkan 2022-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948).

    Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948). oleh Chandrajit P Raut, Yves Boucher, Dan G Duda, Jeffrey A Morgan, Richard Quek, Marek Ancukiewicz, Johanna Lahdenranta, J Paul Eder, George D Demetri, Rakesh K Jain

    Diterbitkan 2012-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Immune modulation by molecularly targeted photothermal ablation in a mouse model of advanced hepatocellular carcinoma and cirrhosis

    Immune modulation by molecularly targeted photothermal ablation in a mouse model of advanced hepatocellular carcinoma and cirrhosis oleh Nina M. Muñoz, Crystal Dupuis, Malea Williams, Katherine Dixon, Amanda McWatters, Jie Zhang, Swathi Pavuluri, Arvind Rao, Dan G. Duda, Ahmed Kaseb, Rahul A. Sheth

    Diterbitkan 2022-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Inter-patient variations of radiation-induced normal-tissue changes in Gd-EOB-DTPA-enhanced hepatic MRI scans during fractionated proton therapy

    Inter-patient variations of radiation-induced normal-tissue changes in Gd-EOB-DTPA-enhanced hepatic MRI scans during fractionated proton therapy oleh Christian Richter, Ovidiu C. Andronesi, Ronald J.H. Borra, Felix Voigt, Steffen Löck, Dan G. Duda, Alexander R. Guimaraes, Theodore S. Hong, Thomas R. Bortfeld, Joao Seco

    Diterbitkan 2019-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients

    Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients oleh Yves Boucher, Ashwin S. Kumar, Jessica M. Posada, Evisa Gjini, Kathleen Pfaff, Mikel Lipschitz, Ana Lako, Dan G. Duda, Scott J. Rodig, F. Stephen Hodi, Rakesh K. Jain

    Diterbitkan 2021-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer

    Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer oleh Eleni Gkika, Elke Firat, Sonja Adebahr, Erika Graf, Ilinca Popp, Gianluca Radicioni, Simon S. Lo, Ursula Nestle, Nils H. Nicolay, Gabriele Niedermann, Dan G. Duda, Anca-L. Grosu

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model

    Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model oleh Wende Li, Sen Li, Ivy X. Chen, Yujiao Liu, Rakesh R. Ramjiawan, Chi-Ho Leung, Leo E. Gerweck, Dai Fukumura, Jay S. Loeffler, Rakesh K. Jain, Dan G. Duda, Peigen Huang

    Diterbitkan 2021-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy

    Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy oleh Yuling Xiao, Jiang Chen, Hui Zhou, Xiaodong Zeng, Zhiping Ruan, Zhangya Pu, Xingya Jiang, Aya Matsui, Lingling Zhu, Zohreh Amoozgar, Dean Shuailin Chen, Xiangfei Han, Dan G. Duda, Jinjun Shi

    Diterbitkan 2022-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer

    Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer oleh Prashant Dogra, Vrushaly Shinglot, Javier Ruiz-Ramírez, Joseph Cave, Joseph D. Butner, Carmine Schiavone, Dan G. Duda, Ahmed O. Kaseb, Caroline Chung, Eugene J. Koay, Vittorio Cristini, Bulent Ozpolat, George A. Calin, Zhihui Wang

    Diterbitkan 2024-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers

    Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers oleh Bolni Marius Nagalo, Camilo Ayala Breton, Yumei Zhou, Mansi Arora, James M. Bogenberger, Oumar Barro, Michael B. Steele, Nathan J. Jenks, Alexander T. Baker, Dan G. Duda, Lewis Rowland Roberts, Stephen J. Russell, Kah Whye Peng, Mitesh J. Borad

    Diterbitkan 2020-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.

    Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. oleh Jeffrey A Meyerhardt, Marek Ancukiewicz, Thomas A Abrams, Deborah Schrag, Peter C Enzinger, Jennifer A Chan, Matthew H Kulke, Brian M Wolpin, Michael Goldstein, Lawrence Blaszkowsky, Andrew X Zhu, Meaghan Elliott, Eileen Regan, Rakesh K Jain, Dan G Duda

    Diterbitkan 2012-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study

    Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study oleh Romualdo Barroso-Sousa, Tanya E. Keenan, Tianyu Li, Nabihah Tayob, Lorenzo Trippa, Ricardo G. Pastorello, Edward T. Richardson III, Deborah Dillon, Zohreh Amoozgar, Beth Overmoyer, Stuart J. Schnitt, Eric P. Winer, Elizabeth A. Mittendorf, Eliezer Van Allen, Dan G. Duda, Sara M. Tolaney

    Diterbitkan 2021-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma

    Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma oleh Eudocia Q. Lee, Alona Muzikansky, Dan G. Duda, Sarah Gaffey, Jorg Dietrich, Lakshmi Nayak, Ugonma N. Chukwueke, Rameen Beroukhim, Lisa Doherty, Caroline Kane Laub, Debra LaFrankie, Brittney Fontana, Jennifer Stefanik, Sandra Ruland, Victoria Caruso, Jennifer Bruno, Keith Ligon, David A. Reardon, Patrick Y. Wen

    Diterbitkan 2019-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival

    Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with surviva... oleh Ovidiu C. Andronesi, Morteza Esmaeili, Ronald J. H. Borra, Kyrre Emblem, Elizabeth R. Gerstner, Marco C. Pinho, Scott R. Plotkin, Andrew S. Chi, April F. Eichler, Jorg Dietrich, S. Percy Ivy, Patrick Y. Wen, Dan G. Duda, Rakesh Jain, Bruce R. Rosen, Gregory A. Sorensen, Tracy T. Batchelor

    Diterbitkan 2017-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma

    Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma oleh Sarinya Kongpetch, Apinya Jusakul, Jing Quan Lim, Cedric Chuan Young Ng, Jason Yongsheng Chan, Vikneswari Rajasegaran, Tse Hui Lim, Kiat Hon Lim, Su Pin Choo, Simona Dima, Irinel Popescu, Dan G. Duda, Veerapol Kukongviriyapan, Narong Khuntikeo, Chawalit Pairojkul, Steven G. Rozen, Patrick Tan, Bin Tean Teh

    Diterbitkan 2020-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies

    A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies oleh Joan How, Siyang Ren, Jennifer Lombardi‐Story, Meghan Bergeron, Julia Foster, Phillip C. Amrein, Andrew M. Brunner, Amir T. Fathi, Hanno Hock, Anna Khachatryan, Hiroto Kikuchi, Mei Rosa Ng, Jenna Moran, Rupa Narayan, Donna Neuberg, Aura Ramos, Tina Som, Meghan Vartanian, Yi‐Bin Chen, Dan G. Duda, Gabriela S. Hobbs

    Diterbitkan 2022-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: